FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978593886> ?p ?o ?g. }

• W1978593886 endingPage "698" @default.
• W1978593886 startingPage "685" @default.
• W1978593886 abstract "The advent of biological therapies for inflammatory bowel disease (IBD) began in 1998 with the approval of infliximab for the treatment of refractory (to conventional agents) Crohn's disease (CD). Since then, the indications for anti-tumor necrosis factor-α (anti-TNFα) therapy have increased to include induction and maintenance of clinical responses and remissions for luminal and fistulizing CD, the treatment of children with CD, and the treatment of adults with ulcerative colitis. Additional utilities of biological therapies have included demonstrable mucosal healing, improvement in quality of life, reduction in surgeries and hospitalizations, and the treatment of extraintestinal manifestations of IBD including central and peripheral arthritis and pyoderma gangrenosum. Natalizumab has also been approved for the treatment of refractory Crohn's in patients who have failed conventional agents and anti-TNFα therapies. Unfortunately, despite the overall effectiveness of biological agents in a spectrum of indications for IBD, a significant proportion of patients do not respond or lose response over time. In this review, we intend to appraise the latest evolution in treatment strategies in IBD and to suggest an evidence-based approach and risk stratification while coping with cases of non-responders or loss of response to biological therapies.We conducted a literature search of English publications listed in the electronic databases of MEDLINE (source PUBMED) and constructed an analytical review based on definitions of response and loss of response, considering potential responsible mechanisms, clinical assessment tools, and finally recommending a practical approach for its prevention and management.Favorable clinical outcome appears to be the consequence of sustained therapeutic drug levels, and the current literature supports a practice of dose adjustments. When immunogenicity develops to a single biological agent, response can be regained by introduction of an alternative biological agent of the same or different class. Efficacy is reduced with second-line agents either within or across classes compared with naive patients. In the absence of direct measurement of drug levels and anti-drug antibodies, clinical judgment is necessary to assess the mechanisms of loss of response, and more empiric decision making may be necessary to determine the choice of second-line biological agents. Optimal treatment strategies are still controversial.It is essential to recognize the spectrum of mechanisms affecting response and loss of response to form a logical and efficient management algorithm, and, perhaps, it is time to incorporate the measurement of trough levels and anti-drug antibodies in the strategy of such an assessment. Prospective controlled trials are direly needed to investigate the optimal tailored management in individual patients who lose response." @default.
• W1978593886 created "2016-06-24" @default.
• W1978593886 creator A5011739304 @default.
• W1978593886 creator A5069738170 @default.
• W1978593886 date "2011-04-01" @default.
• W1978593886 modified "2023-10-18" @default.
• W1978593886 title "Assessing Response and Loss of Response to Biological Therapies in IBD" @default.
• W1978593886 cites W1585045402 @default.
• W1978593886 cites W1596522694 @default.
• W1978593886 cites W1964785646 @default.
• W1978593886 cites W1973123086 @default.
• W1978593886 cites W1979364075 @default.
• W1978593886 cites W1979948289 @default.
• W1978593886 cites W1980521490 @default.
• W1978593886 cites W1985701112 @default.
• W1978593886 cites W1985763670 @default.
• W1978593886 cites W1988152800 @default.
• W1978593886 cites W1989127847 @default.
• W1978593886 cites W1991810959 @default.
• W1978593886 cites W1992628263 @default.
• W1978593886 cites W1997999969 @default.
• W1978593886 cites W1998881470 @default.
• W1978593886 cites W2000500639 @default.
• W1978593886 cites W2001929304 @default.
• W1978593886 cites W2003391401 @default.
• W1978593886 cites W2003904406 @default.
• W1978593886 cites W2006227197 @default.
• W1978593886 cites W2010463972 @default.
• W1978593886 cites W2017295150 @default.
• W1978593886 cites W2022507641 @default.
• W1978593886 cites W2023262456 @default.
• W1978593886 cites W2024644107 @default.
• W1978593886 cites W2026116536 @default.
• W1978593886 cites W2028547258 @default.
• W1978593886 cites W2036868912 @default.
• W1978593886 cites W2039439001 @default.
• W1978593886 cites W2043097326 @default.
• W1978593886 cites W2046628605 @default.
• W1978593886 cites W2047158379 @default.
• W1978593886 cites W2050154180 @default.
• W1978593886 cites W2055513874 @default.
• W1978593886 cites W2056225184 @default.
• W1978593886 cites W2062826169 @default.
• W1978593886 cites W2064661856 @default.
• W1978593886 cites W2067519941 @default.
• W1978593886 cites W2067874068 @default.
• W1978593886 cites W2069702840 @default.
• W1978593886 cites W2072711218 @default.
• W1978593886 cites W2077833843 @default.
• W1978593886 cites W2078621117 @default.
• W1978593886 cites W2081071002 @default.
• W1978593886 cites W2081987637 @default.
• W1978593886 cites W2090685459 @default.
• W1978593886 cites W2092160468 @default.
• W1978593886 cites W2096839909 @default.
• W1978593886 cites W2097148639 @default.
• W1978593886 cites W2100757339 @default.
• W1978593886 cites W2104902789 @default.
• W1978593886 cites W2105532585 @default.
• W1978593886 cites W2106010005 @default.
• W1978593886 cites W2111018767 @default.
• W1978593886 cites W2115865518 @default.
• W1978593886 cites W2117212747 @default.
• W1978593886 cites W2118088660 @default.
• W1978593886 cites W2118559127 @default.
• W1978593886 cites W2119046820 @default.
• W1978593886 cites W2121609590 @default.
• W1978593886 cites W2122735365 @default.
• W1978593886 cites W2124365338 @default.
• W1978593886 cites W2124670599 @default.
• W1978593886 cites W2126510103 @default.
• W1978593886 cites W2131632358 @default.
• W1978593886 cites W2136215457 @default.
• W1978593886 cites W2137775651 @default.
• W1978593886 cites W2138223843 @default.
• W1978593886 cites W2141139109 @default.
• W1978593886 cites W2143068734 @default.
• W1978593886 cites W2144550346 @default.
• W1978593886 cites W2145162151 @default.
• W1978593886 cites W2145245891 @default.
• W1978593886 cites W2146963207 @default.
• W1978593886 cites W2155438550 @default.
• W1978593886 cites W2158288456 @default.
• W1978593886 cites W2159061752 @default.
• W1978593886 cites W2159143303 @default.
• W1978593886 cites W2162766966 @default.
• W1978593886 cites W2164530471 @default.
• W1978593886 cites W2166360124 @default.
• W1978593886 cites W2166771071 @default.
• W1978593886 cites W2168370388 @default.
• W1978593886 cites W2171297959 @default.
• W1978593886 cites W2171341132 @default.
• W1978593886 cites W2319957449 @default.
• W1978593886 cites W2321453230 @default.
• W1978593886 cites W2615184173 @default.
• W1978593886 cites W4230184840 @default.
• W1978593886 cites W4234158969 @default.
• W1978593886 doi "https://doi.org/10.1038/ajg.2011.103" @default.

• next